share_log

HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target

Moomoo 24/7 ·  Mar 18 06:38

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment